DAFTAR PUSTAKA

1. Widiawati, Sayu.2015. Tesis Kadar Interleukin 17 Serum Berkorelasi Positif dengan

Derajat Keparahan Psoriasis Vulgaris. Bali: Universitas Udayana.p.1

2. Gudjonsson, J.E., Elder, J.T. 2012. Psoriasis. In : Wolff K, Goldsmith LA, Katz SI,
Gilchrest BA, Paller AS, Leffell DJ, Eds. Fitzpatricks Dermatology In General Medicine.
8th Ed. New York: McGraw Hill;. p.197-231.
3. Sugito, T.L. 2008. Penyakit papuloeritroskuamosa dan Dermatomikosis Superfisialis
pada Bayi dan Anak. Semarang: Badan Penerbit Universitas Diponegoro. p. 1-56.
4. Langley, R.G.B., Krueger, G.G., Griffiths, C.M. 2005. Psoriasis: epidemiology, clinical
5.
6.
7.
8.

9.
10.
11.

12.
13.
14.

15.

features, and quality of life. Ann Rheum Dis; 64(2): 18-23.

Kilic, A., Cakmak, S. 2013. Psoriasis and comorbidities. EMJ Dermatol; 1:78-85.
Reich, K. 2012. The concept of psoriasis as a systemic inflammation: implications for
disease management. J Eur Acad Dermatol Venereol; 26(2):3-11.
Jobbling, R., Naldi, R. 2006. Assessing the imapct of psoriasis and the relevance of
qualitative research. J Invest Dermatol; 126(7): 1438-40.
Mease, P.J., Menter, M.A. 2006. Quality of life issues in psoriasis and psoriatic arthritis:
outcome measure and therapies from a dermatological perspective. J Am Acad Dermatol;
54(4): 685-704.
Friedewald, V.E., Carther, C. 2008. The editors rountable: psoriasis, inflammation, and
coronary artery disease. Am J Cardiol; 101 (8): 1119- 26.
Mitra, A., Fallen, R.S., Lima, H.C. 2012. Cytokine-based therapy in psoriasis. Clinic Rev
Alleg Immunol; 44(2): 173-82.
Djuanda A. Dermatosis eritroskuamosa. Dalam Djuanda A., Hamzah M.Aisah S. Ilmu
penyakit kulit dan kelamin. Edisi kelima. Jakarta:Fakultas Kedokteran Universitas
Indonesia;2007.h.189-95.
Schon MP. and Boehncke WH. 2005. Psoriasis N. Eng. J. Med; 352(18): 1899-1909.
Gaspari AA. 2006. Innate and Adaptive Immunity and the Patophysiology of Psoriasis. J.
Am Acad Dermatol; 53: 94-100.
Bergboer, J.G., Zeeuwen, P.L., Schalkwijk, J. 2012. Genetics of Psoriasis: Evidence for
Epistatic Interaction between Skin Barier Abnormalities and Immune Deviation. J Invest
Dermatol; 132: 2320-1.
Basavaraj, K.H., Ashok, N.M., Rashmi, R., Praveen, T.K. 2010. The role of drugs in
induction and/or exacerbation of psoriasis. Int J Dermatol; 49: 1351-61.

16. De Rie M.A., Goedkoop A.Y., Bos J.D., 2004. Overview of Psoriasis. DermatolTher; 17:
17.
18.
19.

20.

21.

22.
23.
24.

341-349.
Gudjonsson JE. and Thorarinsson AM., 2003. Streptococcal Throat Infections and
Excerbation of Chronic Plaque Psoriasis: a prospective study. Br. J of Derm; 149:530-4.
Nograles, K.E., Davodovici, B., Krueger, J.G. 2010. New insight in the immunologic
basis of psoriasis. Semin Cutan Med Surg; 29: 3-9.
Betteli, E., Carrier, Y., Gao, W., Korn T., Strom, T.B., Oukka, M. 2006. Reciprocal
development pathways for the generation of pathogenic effector Th17 and regulator cells.
Nature; 441:235-8.
Luo, Q., Zhang, X., Luo, Y., Zhou, X., Lin, L., Li, L., Li, J., Zhang, S., Liu, Y. Mahajan,
R., Handa S. 2013. Pathophysiology of psoriasis. Indian Journal of Dermatology,
Venereology and Leprology; 79(1): 51-59.
Martin, D.A., Towne, J.E., Kricorian, G., Kletkoka, P., Gudjonsson, J.E., Krueger, J.G.
2013. The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical
findings. J invest Dermatol; 133: 17-26.
Chiricozzi, A., Krueger, JA. 2013. IL-17 targeted therapies for psoriasis. Expert Opin.
Investig. Drugs; 22(8): 1-13
Geng A., McBean J., Zeikus P.S., et al. Psoriasis. Dalam Kelly A.P., Taylor S.C., Editors.
Dermatology for skin of color. New York:Mc Graw Hill;2009.h.139-146.
Wolff K., Johnson R.A. Psoriasis. Dalam Wolff K., Johnson R.A.Fitzpatricks color atlas
and synopsis of clinical dermatology. Edisi keenam. New York:Mc Graw Hill;2009.h.5371.